Tony Huge

PCT After SARMs: Why Post-Cycle Therapy Matters Even for ‘Mild’ Compounds

Table of Contents

The Lie of “SARMs Don’t Need PCT”

One of the most dangerous pieces of misinformation circulating in the fitness community is that SARMs (Selective Androgen Receptor Modulators) don’t suppress natural testosterone production and therefore don’t require post-cycle therapy. This claim — repeated endlessly on forums, Reddit, and social media — has led thousands of young men to crash their hormones without any recovery plan, resulting in weeks or months of miserable low-testosterone symptoms and potentially lasting HPG axis damage.

Let me be absolutely clear: every SARM that’s potent enough to build meaningful muscle is also potent enough to suppress your natural testosterone production. The “selective” in Selective Androgen Receptor Modulator refers to tissue selectivity (affecting muscle more than prostate, in theory) — not selectivity in terms of HPG axis suppression. If a compound activates androgen receptors strongly enough to stimulate muscle growth, it activates androgen receptors in the hypothalamus strongly enough to suppress GnRH, LH, and FSH. This is a direct application of the Tony Huge Laws of Biochemistry Physics — receptor activation in one system (muscle) inevitably triggers feedback mechanisms in another (the HPTA).

How SARMs Suppress Testosterone

The mechanism is straightforward and unavoidable. SARMs bind to androgen receptors throughout the body, including in the hypothalamus. The hypothalamus doesn’t distinguish between testosterone, DHT, and a SARM molecule sitting on its androgen receptor — it simply detects that androgen signaling is present and reduces GnRH output in response. Less GnRH means less LH from the pituitary. Less LH means less testosterone from the testicles.

Bloodwork studies on SARM users have documented significant suppression from virtually every commonly used SARM. Ostarine (MK-2866) at 25mg daily suppresses testosterone by 30-50% within 4 weeks. LGD-4033 (Ligandrol) at 10mg daily can suppress testosterone by 50-70%. RAD-140 (Testolone) at 10-20mg daily produces suppression comparable to moderate-dose testosterone. YK-11 and S-23 are among the most suppressive, with some users reporting near-complete HPG axis shutdown.

The degree of suppression depends on the specific SARM, the dose, the duration of use, and individual sensitivity. But the direction is universal — every SARM suppresses to some degree, and any claim otherwise is either ignorant or dishonest. For a deeper understanding of how these compounds compare, see our SARMs vs Steroids: The Honest Comparison.

What Happens Without PCT

When you stop a SARM cycle without PCT, your HPG axis is suppressed — your LH and FSH are low, your testicles have been understimulated, and your natural testosterone production is in the gutter. The body will eventually recover on its own, but the timeline is unpredictable and the recovery period is genuinely miserable.

During the recovery period, men typically experience severe fatigue and lethargy, depression and mood instability, loss of libido and erectile dysfunction, rapid loss of the muscle gained during the SARM cycle (without adequate testosterone to maintain it), increased fat gain (low testosterone promotes fat storage), brain fog and cognitive impairment, and joint pain (estrogen often crashes alongside testosterone).

This recovery can take 4-12 weeks without intervention — sometimes longer, particularly with more suppressive compounds or longer cycles. During this time, you’re losing the gains you made, feeling terrible, and potentially damaging relationships and work performance. It’s entirely preventable with proper PCT.

The PCT Protocol for SARMs

The goal of PCT is to rapidly restart natural testosterone production by stimulating the HPG axis to resume normal function. The approach depends on the degree of suppression.

For mild suppression (ostarine at low doses for short cycles): Enclomiphene at 12.5-25mg daily for 4 weeks is usually sufficient. Enclomiphene blocks estrogen at the hypothalamic receptor, removing the negative feedback and allowing LH and FSH to rise. Since mild SARM cycles haven’t severely impaired the HPG axis, this gentle stimulation is enough to restore normal function quickly.

For moderate suppression (LGD-4033, RAD-140 at standard doses for 8 weeks): Enclomiphene at 25mg daily for 4-6 weeks, or Nolvadex (tamoxifen) at 20mg daily for 4 weeks. Consider adding HCG at 250-500 IU every other day for the first 2 weeks to directly stimulate the testicles before transitioning to the SERM. Bloodwork at week 4 of PCT to verify recovery.

For heavy suppression (S-23, YK-11, stacked SARMs, or extended cycles): Full PCT protocol comparable to steroid PCT — HCG at 500 IU every other day for 2-3 weeks to reactivate testicular function, followed by Nolvadex 20mg or Clomiphene 25mg daily for 4-6 weeks, with bloodwork at week 4 and week 8 to confirm recovery. This is similar to the approach outlined in our guide on How to Cycle Steroids Safely.

Interesting Perspectives

While the necessity of PCT is clear, the conversation around SARMs and recovery is evolving. Some biohackers are exploring “mini-PCT” or “on-cycle support” protocols using very low-dose SERMs like 6.25mg Enclomiphene EOD during a SARM cycle to mitigate suppression before it happens, attempting to keep the HPTA online. The theory is to provide just enough estrogen receptor blockade at the hypothalamus to prevent the negative feedback signal, though this remains experimental and requires precise dosing to avoid blunting the SARM’s efficacy.

Another emerging angle is the use of peptide therapies like Kisspeptin-10 or GnRH pulses post-cycle to attempt a more “physiological” restart of the axis, rather than the blunt pharmacological stimulation of SERMs. The idea is to mimic the body’s natural pulsatile secretion to gently nudge the system back online, potentially with fewer side effects. However, this is far more complex than a standard SERM protocol.

There’s also a contrarian view, though not one I endorse, that for very short, low-dose cycles of the mildest SARMs, a robust natural recovery protocol—using high-dose Fadogia Agrestis, Tongkat Ali, intense weight training, and optimized sleep—might suffice for certain hyper-responders. This ignores individual variability and the basic Tony Huge Laws of Biochemistry Physics concerning receptor occupancy and feedback loops, making it a risky gamble.

The Natty Plus Perspective on SARMs

The Natty Plus Protocol generally doesn’t include SARMs in its recommended interventions, and the PCT requirement is one of the reasons why. If a compound suppresses your HPG axis, it violates a core Natty Plus principle: working with your body’s natural production rather than overriding it. For those seeking enhancement without suppression, exploring the Future of Performance Enhancement beyond traditional androgens is key.

The paradox of SARMs is that they’re often marketed to men who want gains without “real steroids” — but their mechanism of action (androgen receptor activation with HPG suppression) IS the mechanism of steroids, just with a potentially more favorable tissue selectivity profile. You’re getting a steroid-like effect with steroid-like suppression, packaged in a pill form that creates the illusion of simplicity. Understand the full context by reading The Truth About SARMs: Are They Really Safer Than Steroids?.

For men who have used or choose to use SARMs, proper PCT is non-negotiable. The alternative — suffering through weeks of hormonal depression and losing your gains — defeats the entire purpose of using the compounds in the first place. Get your PCT compounds BEFORE starting the cycle, plan the duration and dosing in advance, and commit to bloodwork verification of recovery before considering any further cycles. For a comprehensive look at all SARMs, visit our hub page: SARMs: The Complete Guide.

Citations & References

While direct clinical studies on SARM PCT protocols are limited, the following research establishes the suppressive effects of SARMs, forming the biochemical basis for PCT necessity.

  1. Basaria, S., et al. (2013). “The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men.” Journals of Gerontology: Series A. Key Finding: LGD-4033 administration dose-dependently suppressed serum total testosterone, LH, and FSH.
  2. Kearbey, J. D., et al. (2007). “Pharmacokinetics of S-22, a Selective Androgen Receptor Modulator, in Rats.” Drug Metabolism and Disposition. Note: Early preclinical data showing the androgenic activity and potential for HPTA feedback of SARM compounds.
  3. Mohler, M. L., et al. (2009). “An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics for Androgen-Responsive Diseases.” Expert Opinion on Investigational Drugs. Context: Reviews the mechanism of action of SARMs and their interaction with the androgen receptor, including central feedback.
  4. Solomon, Z. J., et al. (2019). “Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications.” Sexual Medicine Reviews. Key Point: Summarizes clinical trial data indicating that SARMs suppress endogenous testosterone production, necessitating monitoring and management.
  5. Thevis, M., et al. (2011). “Mass spectrometric characterization of selective androgen receptor modulators (SARMs).” Journal of Mass Spectrometry. Context: Analytical chemistry study identifying SARMs and their metabolites, underpinning the detection of these compounds in athletes and their pharmacological presence.